GLP1-RAs also have a positive cardiovascular outcome in T2DM patients, reducing cardiovascular events and mortality, which can be explained by their anti-inflammatory and anti-atherogenic properties [174]; indeed, these agents have a number of important extra-pancreatic cardiometabolic beneficial actions, as summarized in Figure 4 [175,176]. Here, GCG is linked to type 2 diabetes mellitus.